Ubrelvy Tablet
Product Images NDC 85766-280

5 FDA label images from Sportpharm Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ubrelvy (NDC 85766-280). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100 (Label 100mg)

100 (Label 100mg)
Packaging labels for UBRELVY (ubrogepant) Tablets 100 mg relabeled for SportPharm. The labels list quantities of 1, 10, 16, and 30 tablets. Each label includes the NDC, manufacturer AbbVie Inc., drug status RX, and storage instructions. Labels feature a QR code and caution about dispensing without prescription.*
FDA Label Image

50 (Label 50mg)

50 (Label 50mg)
Repackaged labeling for UBRELVY (ubrogepant) Tablets 50 mg by Sportpharm. The labels show various quantities: 1, 10, 16, and 30 tablets. Each label includes the NDC codes, manufacturer AbbVie Inc., and directions to see the package insert. They feature a QR code and warnings about prescription status and storage instructions.*
FDA Label Image

The Following Structural Formula For Ubrelvy Is Ubrogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Ubrogepant Is (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl (Ubrelvy 01)

The Following Structural Formula For Ubrelvy Is Ubrogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Ubrogepant Is (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl (Ubrelvy 01)
Chemical structure of ubrogepant, the active ingredient in UBRELVY tablets. The diagram depicts the molecular arrangement including multiple rings, carbon, nitrogen, oxygen atoms, and a trifluoromethyl group.*
FDA Label Image

Figure 1: Percentage Of Patients Achieving Pain Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 02)

Figure 1: Percentage Of Patients Achieving Pain Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 02)
A line graph showing percent of participants achieving pain freedom over time from dose (0 to 2 hours) for UBRELVY tablets in 50 mg and 100 mg strengths compared to placebo. The y-axis indicates percent achieving pain freedom from 0% to 100%, and the x-axis shows time from 0 to 2 hours. Three lines represent UBRELVY 100 mg, UBRELVY 50 mg, and placebo, illustrating their comparative pain relief effect over the two-hour period.*
FDA Label Image

Figure 2: Percentage Of Patients Achieving Mbs Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 03)

Figure 2: Percentage Of Patients Achieving Mbs Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 03)
A line chart showing the percent achieving MBS (most bothersome symptom) freedom over time in hours from dose for UBRELVY tablets at 50 mg and 100 mg strengths, compared with placebo. The x-axis represents time from 0 to 2 hours, and the y-axis shows percent freedom from 0% to 100%. Two UBRELVY doses show increasing symptom freedom up to about 39% at 2 hours, while placebo reaches approximately 27%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.